Enveric Biosciences Inc (ENVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,267 | 7,081 | 12,562 | 17,724 | 21,201 |
| TOTAL | $5,827 | $8,900 | $14,839 | $18,432 | $22,267 |
| Non-Current Assets | |||||
| PPE Net | 539 | 595 | 639 | 678 | 713 |
| Intangibles | 253 | 295 | 338 | 380 | 7,787 |
| Other Non-Current Assets | 0 | 10 | 37 | 64 | 89 |
| TOTAL | $792 | $900 | $1,014 | $1,121 | $8,589 |
| Total Assets | $6,619 | $9,800 | $15,853 | $19,553 | $30,855 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,098 | 1,235 | 1,793 | 463 | 710 |
| Other current liabilities | 1,552 | 2,182 | 1,877 | 1,763 | 1,799 |
| TOTAL | $4,184 | $4,926 | $4,438 | $3,996 | $2,598 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 1,008 | 885 | 3,931 |
| TOTAL | $N/A | $N/A | $1,008 | $885 | $5,417 |
| Total Liabilities | $4,184 | $4,926 | $5,447 | $4,881 | $8,015 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 13 | 12 | 12 | 12 | 12 |
| Common Shares | 22 | 21 | 21 | 21 | 21 |
| Retained earnings | -93,064 | -90,241 | -83,885 | -79,208 | -70,530 |
| Other shareholders' equity | -536 | -546 | -535 | -537 | -641 |
| TOTAL | $2,436 | $4,875 | $10,406 | $14,672 | $22,840 |
| Total Liabilities And Equity | $6,619 | $9,800 | $15,853 | $19,553 | $30,855 |